DUBLIN--(BUSINESS WIRE)--The "Global Anti-Fungal Drugs Market - Segmented by Drug type, Therapeutic Indication and Geography - Growth, Trends and Forecasts (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.
The global anti-fungal drugs market is expected to register a CAGR of 3.7% during the forecast period, 2018 to 2023.
With rising popularity of over-the-counter (OTC) drugs, many patients prefer them to obtaining a prescription from a healthcare professional. Numerous common and harmless fungal infections are left untreated by patients, owing to medical costs and logistical constraints. These have directly contributed to the rise in the usage of OTC drugs, as these infections can be treated by OTC drugs, owing to their ease of availability.
Increasing awareness about myriad fungal infections and increasing government and corporate funding are some other drivers of the market.
North America dominates the market due to increasing awareness of fungal infections with the growing incidence of antifungal infections and increasing government and corporate funding in the industry.
Companies Mentioned
- Abbott Laboratories
- Pfizer
- Glaxosmithkline
- Bayer Healthcare
- Novartis
- Sanofi-Aventis
- Merck & Co.
- Kramer Laboratories
- Enzon Pharmaceuticals
- Gilead
Key Topics Covered
1. Introduction
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
7. Market Segmentation
8. Competitive Landscape
9. Key Players
10. Future of the Market
For more information about this report visit https://www.researchandmarkets.com/research/lqgw3k/global?w=4
